Subscribe to RSS
Prognostic Factors of the Primary Central Nervous System Lymphoma: Clinical Experience from a Tertiary Care Center in the Middle EastFunding None.
Aim Primary central nervous system lymphoma (PCNSL) is a rare extra nodal non-Hodgkin's lymphoma. The optimal treatment for PCNSL is still unclear. In this study, we present our experience with management of PCNSL in a tertiary care center in Iran.
Methods In this retrospective study, 58 patients with tissue diagnosis of PCNSL were studied. All patients were treated with chemotherapy including intravenous high-dose methotrexate, rituximab and temozolomide and radiotherapy by the same oncologist. Statistical analysis was performed using SPSS.
Results The mean overall survival (OS) in this study was 37.4 ± 13.6 months and the mean progression free survival (PFS) was 35.1 ± 9.8 months. The mean time to progression was 15.2 ± 8.79 months among 8 patients who experienced progression in this series. Finding of a positive CSF cytology was not linked with disease progression, while HIV infection and multifocal involvement at initial presentation were strongly linked to a lower PFS. The single most important factor affecting the OS was the histopathologic type of the PCNSL; two of the three patients who died from their disease in this series had non-B cell PCNSL, whereas only one patient with DLBCL died because of brainstem involvement.
Conclusion The results of this study show a lower rate of HIV-infection in patients with PCNSL as compared to the series from the western countries. Non-B cell histopathology and HIV-infection were found to be associated with the dismal prognosis.
Article published online:
27 March 2023
© 2023. Asian Congress of Neurological Surgeons. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
- 1 Yuan XG, Huang YR, Yu T. et al. Primary central nervous system lymphoma in China: a single-center retrospective analysis of 167 cases. Ann Hematol 2020; 99 (01) 93-104
- 2 Fox J, Ajinkya S, Houston P. et al. Seizures in patents with primary central nervous system lymphoma: prevalence and associated features. J Neurol Sci 2019; 400: 34-38
- 3 Dalia S, Forsyth P, Chavez J. et al. Primary B-cell CNS lymphoma clinicopathologic and treatment outcomes in 89 patients from a single tertiary care center. Int J Hematol 2014; 99 (04) 450-456
- 4 Löw S, Han CH, Batchelor TT. Primary central nervous system lymphoma. Ther Adv Neurol Disord 2018; 11: 1756286418793562
- 5 Dandachi D, Ostrom QT, Chong I. et al. Primary central nervous system lymphoma in patients with and without HIV infection: a multicenter study and comparison with U.S national data. Cancer Causes Control 2019; 30 (05) 477-488
- 6 Grommes C, DeAngelis LM. Primary CNS lymphoma. J Clin Oncol 2017; 35 (21) 2410-2418
- 7 Norden AD, Drappatz J, Wen PY, Claus EB. Survival among patients with primary central nervous system lymphoma, 1973-2004. J Neurooncol 2011; 101 (03) 487-493
- 8 Yadav BS, Mahajan R, Sharma SC, Gupta A, Kumar S. Primary central nervous system lymphoma: an experience of a regional cnncer center from India. J Radiat Cancer Res 2019; 10 (02) 104-107
- 9 Kiewe P, Fischer L, Martus P, Thiel E, Korfel A. Meningeal dissemination in primary CNS lymphoma: diagnosis, treatment, and survival in a large monocenter cohort. Neuro-oncol 2010; 12 (04) 409-417
- 10 Ghesquières H, Drouet Y, Sunyach MP. et al. Evidence of time-dependent prognostic factors predicting early death but not long-term outcome in primary CNS lymphoma: a study of 91 patients. Hematol Oncol 2013; 31 (02) 57-64
- 11 Han CH, Batchelor TT. Diagnosis and management of primary central nervous system lymphoma. Cancer 2017; 123 (22) 4314-4324
- 12 Neuhauser M, Roetzer T, Oberndorfer S. et al. Increasing use of immunotherapy and prolonged survival among younger patients with primary CNS lymphoma: a population-based study. Acta Oncol 2019; 58 (07) 967-976
- 13 Liu J, Wang Y, Liu Y. et al. Immunohistochemical profile and prognostic significance in primary central nervous system lymphoma: Analysis of 89 cases. Oncol Lett 2017; 14 (05) 5505-5512
- 14 Ney DE, Reiner AS, Panageas KS, Brown HS, DeAngelis LM, Abrey LE. Characteristics and outcomes of elderly patients with primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center experience. Cancer 2010; 116 (19) 4605-4612
- 15 Lin CH, Yang CF, Yang HC. et al. Risk prediction for early mortality in patients with newly diagnosed primary CNS lymphoma. J Cancer 2019; 10 (17) 3958-3966